SC
VNRX icon

Skylands Capital’s VolitionRx Ltd VNRX Stock Holding History

Skylands Capital’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,543
Closed -$62K – 171
2018
Q2 		$62K Sell
1,543
-4,512
-75% -$202K 0.01% 154
2018
Q1 		$291K Buy
+6,055
New +$354K 0.04% 140

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Skylands Capital's VNRX Position: Q3 2018 in Review

Skylands Capital sold out of VolitionRx Ltd (VNRX) in Q3 2018, closing a stake of 1,543 shares — an estimated $62K sold.

Skylands Capital first reported a position in VNRX in Q1 2018 and held it in 2 quarters. The position peaked at $291K in Q1 2018. 27 funds tracked by Wall St. Rank hold VNRX as of Q3 2018.

  • Skylands Capital reported no remaining VolitionRx Ltd position as of Q3 2018 after selling out during the quarter.
  • Skylands Capital sold 1,543 VolitionRx Ltd shares in Q3 2018, an estimated $62K.
  • Skylands Capital first reported a position in VolitionRx Ltd in Q1 2018 and held it in 2 quarters.
  • Skylands Capital's VolitionRx Ltd position peaked at $291K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q3 2018.

Based on Skylands Capital's 13F filing for Q3 2018, filed 22 Oct 2018.